Mechanistic basis for overcoming platinum resistance using copper chelating agents

Molecular Cancer Therapeutics

Volumn 11, Issue 11, 2012, Pages 2483-2494

  Liang, Zheng D ^a   Long, Yan ^a   Tsai, Wen Bin ^a   Fu, Siqing ^a   Kurzrock, Razelle ^a   Gagea Iurascu, Mihai ^a   Zhang, Fan ^a   Chen, Helen H W ^c   Hennessy, Bryan T ^d   Mills, Gordon B ^b   Savaraj, Niramol ^a   Kuo, Macus Tien ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; CISPLATIN; COPPER; PLATINUM;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL KILLING; CELL LINE; CHELATION; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HOMEOSTASIS; HUMAN; OUTCOME ASSESSMENT; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CHELATING AGENTS; CISPLATIN; COPPER; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PLATINUM; RNA, MESSENGER; STRESS, PHYSIOLOGICAL; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866360659     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0580     Document Type: Article

References (35)

1. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-28.
2. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84. (Pubitemid 47106628)
3. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 2002;99:14298-302. (Pubitemid 35257666)
4. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 2006;70:1390-4. (Pubitemid 44435991)
5. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 2010;77:887-94.
6. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007;26:71-83. (Pubitemid 46452185)
7. Chen HH, Song IS, Hossain A, Choi MK, Yamane Y, Liang ZD, et al. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol Pharmacol 2008;74:697-704.
8. Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010;17:574-83.
9. Liang ZD, Tsai WB, Lee MY, Savaraj N, Kuo MT. Specificity protein 1 (Sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression. Mol Pharmacol 2012;81:455-64.
10. Song IS, Chen HH, Aiba I, Hossain A, Liang ZD, Klomp LW, et al. Transcription factor Sp1 plays an important role in the regulation of copper homeostasis in mammalian cells. Mol Pharmacol 2008;74:705-13.
11. Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther 2012;11:1221-5.
12. Liang ZD, Stockton D, Savaraj N, Tien Kuo M. Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol 2009;76:843-53.
13. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986;31:229-34. (Pubitemid 16104025)
14. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208. (Available from: www.ncbi.nlm.nih. gov/geo, accession #GSE9899).
15. The R project for statistical computing. (Available from: http://www.r-project.org/).
16. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004;3:1543-9. (Pubitemid 40136709)
17. Kim BE, Nevitt T, Thiele DJ. Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 2008;4:176-85. (Pubitemid 351264130)
18. Kuo MT, Fu S, Savaraj N, Chen HHW. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res 2012;71:1-6.
19. Gupta A, Lutsenko S. Human copper transporters: mechanism, role in human diseases and therapeutic potential. Future Med Chem 2009;1:1125-42.
20. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 1989;59:527-34. (Pubitemid 19111741)
21. Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985;45:4970-9. (Pubitemid 16236181)
22. Saunders DE, Christensen C, Williams JR, Boyer P, Duvillard P, Chiric E, et al. Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. Anticancer Drugs 1995;6:562-9.
23. Fraifeld V, Seidman R, Sagi O, Muradian K, Wolfson M. Aurintricarboxylic acid decreases proliferative potential of SKOV3 and MCF7 human carcinoma cells. Anticancer Res 2001;21:1975-8. (Pubitemid 32728939)
24. Brewer GJ. Anticopper therapy against cancer and diseases of inflammation and fibrosis. Drug Discov Today 2005;10:1103-9. (Pubitemid 41327785)
25. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31. (Pubitemid 46810280)
26. Lee J, Prohaska JR, Dagenais SL, Glover TW, Thiele DJ. Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene 2000;254:87-96.
27. van den Berghe PV, Klomp LW. Posttranslational regulation of copper transporters. J Biol Inorg Chem 2010;15:37-46.
28. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008;48:495-535. (Pubitemid 351738162)
29. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20. (Pubitemid 41130944)
30. Blair BG, Larson CA, Adams PL, Abada PB, Safaei R, Howell SB. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol Pharmacol 2009;77:912-21.
31. Dmitriev OY. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B. Biochem Cell Biol 2011;89:138-47.
32. Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ, Brewer G, et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 2006;71:168-75.
33. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 2006;12:6876-83. (Pubitemid 44974479)
34. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009;35:32-46.
35. Kuo HW, Chen SF, Wu CC, Chen DR, Lee JH. Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol Trace Elem Res 2002;89:1-11. (Pubitemid 35222150)